VWM
ALNY icon

Venturi Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Venturi Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-252
Closed -$59.3K – 610
2024
Q4 		$59.3K Buy
252
+248
+6,200% +$65.2K ﹤0.01% 967
2024
Q3 		$1.1K Buy
+4
New +$1.04K ﹤0.01% 1767

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Venturi Wealth Management's ALNY Position: Q1 2025 in Review

Venturi Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 252 shares — an estimated $59.3K sold.

Venturi Wealth Management first reported a position in ALNY in Q3 2024 and held it in 2 quarters. The position peaked at $59.3K in Q4 2024. 626 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Venturi Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Venturi Wealth Management sold 252 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $59.3K.
  • Venturi Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Venturi Wealth Management's Alnylam Pharmaceuticals position peaked at $59.3K in Q4 2024.
  • 626 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Venturi Wealth Management's 13F filing for Q1 2025, filed 6 May 2025.